Latest Investor Relations News

Haranga Resources has raised $14 million through an oversubscribed placement led by Collins St Gold Fund, aiming to fast-track exploration and development at its Lincoln and Ibel South gold projects.

WhiteHawk Limited has announced the listing of nearly 93.5 million free-attaching options issued under its August 2025 placement, exercisable at $0.02 and expiring in 2028. These options, approved by shareholders, could raise close to $1.87 million if fully exercised.

Garda Property Group has announced its distribution components for the year ending June 2026, highlighting key tax elements and a total cash payout scheduled for mid-October.

BlackWall Limited has confirmed the exact ratio for its in-specie dividend distribution, allocating one WOT security for every 24 BWF shares held as of the record date.

Magmatic Resources has responded to ASX queries over a recent spike in its share price and trading volume, confirming no undisclosed information exists. The company points to pending assay results from its Weebo Gold Project drilling as the likely catalyst for market interest.

Imagion Biosystems has completed the second tranche of its $3.5 million placement, raising $2.85 million to advance its proprietary MagSense® imaging technology targeting breast, prostate, and ovarian cancers.

Advance Metals Limited has responded to an ASX query clarifying its compliance with disclosure rules and marketing practices, while updating on its funding status and capital raise plans.

Washington H. Soul Pattinson and Brickworks have finalized their share schemes, exchanging existing shares for Topco shares and marking Brickworks’ imminent ASX delisting.

Noxopharm Limited has secured an extension on $2.6 million of convertible notes and obtained a $1.25 million unsecured loan to bolster working capital, pending shareholder approval.

Advance Metals Limited explains its recent share price jump and trading volume spike as driven by investor relations efforts and an upcoming assay results announcement from its Myrtleford Project.

Elanor Investors Group is set to reclaim over 12 million stapled securities from Challenger’s Fidante subsidiary as part of unwinding their strategic partnership, reshaping ownership stakes and signaling a new chapter for the funds manager.

PYC Therapeutics announces the resignation of CEO Dr Rohan Hockings, appointing Chairman Alan Tribe as interim Managing Director while searching for a permanent replacement.